On Thursday 14 October, the European Medicines Agency (EMA) announced that it had begun evaluating a new candidate treatment for Covid-19 developed by the pharmaceutical company AstraZeneca. This candidate treatment, called Evusheld - or AZD7442 - is a combination of two monoclonal antibodies: tixagevimab and cilgavimab. The EMA is currently evaluating data from laboratory and animal studies. It says that it “will evaluate more data on the quality, safety and effectiveness of the medicine as they become available”. The aim of this treatment is to prevent the virus from entering the body’s cells and causing an infection. Evusheld is the eighth candidate treatment for Covid-19 to undergo a rolling review by the EMA. For four of these treatments, a market authorisation application has already been submitted and is also under review. For more details: https://bit.ly/3uOMP9i (AC)